Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose DCR-PHXC in primary hyperoxaluria type 3
NL-OMON49809Phase 1Not yet recruiting
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Sep 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, double-blind trial of nedosiran in primary hyperoxaluria type 3 (PH3) (2 arms), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Change from baseline in clinical laboratory tests and 3 more. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
nedosiran
03
Conditions
primary hyperoxaluria type 3 (PH3)
Beyond the preview
Go deeper on NL-OMON49809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49809.